June 1, 1984The Journal of Urology
Phase II Trial of Doxorubicin in Bidimensionally Measurable Prostatic Adenocarcinoma
Why the study?
Does intravenous doxorubicin induce tumor response in patients with metastatic adenocarcinoma of the prostate?
Population
52 patients with metastatic adenocarcinoma of the prostate, including 41 with bidimensionally measurable…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Intravenous doxorubicin shows marginal activity in metastatic prostate cancer; leaves open any role in modern regimens pending prospective trials.
Structured PICO
Does intravenous doxorubicin induce tumor response in patients with metastatic adenocarcinoma of the prostate?
P
Population
52 patients with metastatic adenocarcinoma of the prostate, including 41 with bidimensionally measurable soft tissue lesions. Prior therapy in the measurable disease group included hormonal manipulation (n=39), irradiation (n=39), and cytotoxic drugs (n=19).
I
Intervention
Intravenous doxorubicin (30 to 60 mg/m2 every 3 weeks)
O
Outcome
Tumor response (partial remission, minor response, stabilization) and survivalsurrogate
Intravenous doxorubicin has marginal activity in treating soft tissue lesions in patients with advanced prostatic cancer.
Limitations
- patient selection bias
- treatment schedule
Cite This Study
Scher et al. (1984) studied this question.